<!DOCTYPE html>
<!-- saved from url=(0114)https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease: Asthma</title>
<!-- Copyright (c) 2010-2015 The MathJax Consortium -->
<meta name="viewport" content="width=device-width; initial-scale=1.0;">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<link media="screen, print" rel="stylesheet" href="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/bootstrap.min.css"><link media="screen, print" rel="stylesheet" href="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/bootstrap-theme.min.css"><link media="screen, print" rel="stylesheet" href="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/main.css"><script src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/jquery.min.js.download" type="text/javascript"></script>
<script src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/bootstrap.min.js.download" type="text/javascript"></script>
<script src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/bibCit.js.download" type="text/javascript"></script>
<script src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/divTab.js.download" type="text/javascript"></script>
<script type="text/javascript" src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/MathJax.js.download"></script>
<script type="text/x-mathjax-config;executed=true">MathJax.Hub.Config({tex2jax: {inlineMath: [['$','$'], ['\\(','\\)']]}});</script>
<style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 2px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 2px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: 1em}
.MathJax_MenuRadioCheck.RTL {right: 1em; left: auto}
.MathJax_MenuLabel {padding: 2px 2em 4px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #CCCCCC; margin: 4px 1px 0px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: Highlight; color: HighlightText}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style><style type="text/css">.MathJax_Preview .MJXf-math {color: inherit!important}
</style><style type="text/css">.MJX_Assistive_MathML {position: absolute!important; top: 0; left: 0; clip: rect(1px, 1px, 1px, 1px); padding: 1px 0 0 0!important; border: 0!important; height: 1px!important; width: 1px!important; overflow: hidden!important; display: block!important; -webkit-touch-callout: none; -webkit-user-select: none; -khtml-user-select: none; -moz-user-select: none; -ms-user-select: none; user-select: none}
.MJX_Assistive_MathML.MJX_Assistive_MathML_Block {width: 100%!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MJXp-script {font-size: .8em}
.MJXp-right {-webkit-transform-origin: right; -moz-transform-origin: right; -ms-transform-origin: right; -o-transform-origin: right; transform-origin: right}
.MJXp-bold {font-weight: bold}
.MJXp-italic {font-style: italic}
.MJXp-scr {font-family: MathJax_Script,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-frak {font-family: MathJax_Fraktur,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-sf {font-family: MathJax_SansSerif,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-cal {font-family: MathJax_Caligraphic,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-mono {font-family: MathJax_Typewriter,'Times New Roman',Times,STIXGeneral,serif}
.MJXp-largeop {font-size: 150%}
.MJXp-largeop.MJXp-int {vertical-align: -.2em}
.MJXp-math {display: inline-block; line-height: 1.2; text-indent: 0; font-family: 'Times New Roman',Times,STIXGeneral,serif; white-space: nowrap; border-collapse: collapse}
.MJXp-display {display: block; text-align: center; margin: 1em 0}
.MJXp-math span {display: inline-block}
.MJXp-box {display: block!important; text-align: center}
.MJXp-box:after {content: " "}
.MJXp-rule {display: block!important; margin-top: .1em}
.MJXp-char {display: block!important}
.MJXp-mo {margin: 0 .15em}
.MJXp-mfrac {margin: 0 .125em; vertical-align: .25em}
.MJXp-denom {display: inline-table!important; width: 100%}
.MJXp-denom > * {display: table-row!important}
.MJXp-surd {vertical-align: top}
.MJXp-surd > * {display: block!important}
.MJXp-script-box > *  {display: table!important; height: 50%}
.MJXp-script-box > * > * {display: table-cell!important; vertical-align: top}
.MJXp-script-box > *:last-child > * {vertical-align: bottom}
.MJXp-script-box > * > * > * {display: block!important}
.MJXp-mphantom {visibility: hidden}
.MJXp-munderover {display: inline-table!important}
.MJXp-over {display: inline-block!important; text-align: center}
.MJXp-over > * {display: block!important}
.MJXp-munderover > * {display: table-row!important}
.MJXp-mtable {vertical-align: .25em; margin: 0 .125em}
.MJXp-mtable > * {display: inline-table!important; vertical-align: middle}
.MJXp-mtr {display: table-row!important}
.MJXp-mtd {display: table-cell!important; text-align: center; padding: .5em 0 0 .5em}
.MJXp-mtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-mlabeledtr {display: table-row!important}
.MJXp-mlabeledtr > .MJXp-mtd:first-child {padding-left: 0}
.MJXp-mlabeledtr:first-child > .MJXp-mtd {padding-top: 0}
.MJXp-merror {background-color: #FFFF88; color: #CC0000; border: 1px solid #CC0000; padding: 1px 3px; font-style: normal; font-size: 90%}
.MJXp-scale0 {-webkit-transform: scaleX(.0); -moz-transform: scaleX(.0); -ms-transform: scaleX(.0); -o-transform: scaleX(.0); transform: scaleX(.0)}
.MJXp-scale1 {-webkit-transform: scaleX(.1); -moz-transform: scaleX(.1); -ms-transform: scaleX(.1); -o-transform: scaleX(.1); transform: scaleX(.1)}
.MJXp-scale2 {-webkit-transform: scaleX(.2); -moz-transform: scaleX(.2); -ms-transform: scaleX(.2); -o-transform: scaleX(.2); transform: scaleX(.2)}
.MJXp-scale3 {-webkit-transform: scaleX(.3); -moz-transform: scaleX(.3); -ms-transform: scaleX(.3); -o-transform: scaleX(.3); transform: scaleX(.3)}
.MJXp-scale4 {-webkit-transform: scaleX(.4); -moz-transform: scaleX(.4); -ms-transform: scaleX(.4); -o-transform: scaleX(.4); transform: scaleX(.4)}
.MJXp-scale5 {-webkit-transform: scaleX(.5); -moz-transform: scaleX(.5); -ms-transform: scaleX(.5); -o-transform: scaleX(.5); transform: scaleX(.5)}
.MJXp-scale6 {-webkit-transform: scaleX(.6); -moz-transform: scaleX(.6); -ms-transform: scaleX(.6); -o-transform: scaleX(.6); transform: scaleX(.6)}
.MJXp-scale7 {-webkit-transform: scaleX(.7); -moz-transform: scaleX(.7); -ms-transform: scaleX(.7); -o-transform: scaleX(.7); transform: scaleX(.7)}
.MJXp-scale8 {-webkit-transform: scaleX(.8); -moz-transform: scaleX(.8); -ms-transform: scaleX(.8); -o-transform: scaleX(.8); transform: scaleX(.8)}
.MJXp-scale9 {-webkit-transform: scaleX(.9); -moz-transform: scaleX(.9); -ms-transform: scaleX(.9); -o-transform: scaleX(.9); transform: scaleX(.9)}
.MathJax_PHTML .noError {vertical-align: ; font-size: 90%; text-align: left; color: black; padding: 1px 3px; border: 1px solid}
</style></head>
<body id="main"><div id="MathJax_Message" style="display: none;"></div><banner class="headerBanner"><table width="100%" role="presentation"><tbody><tr><td><div class="utilities-area"><div class="logo-section"><div class="show-for-large-up"><a class="navbar-brand" href="http://www.acm.org/"> <img alt="ACM Logo" class="img-responsive" src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/acm_logo.jpg"></a></div><div class="hide-for-large-up"><a class="navbar-brand" href="http://www.acm.org/"> <img alt="ACM Logo" class="img-responsive" src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/acm_logo_mobile.jpg"></a></div></div></div></td></tr><tr height="50px"><td align="left"><button class="ArtNav" id="ArtNav" onclick="openNav(this)" tabindex="0"><span aria-hidden="true">☰</span><span class="ArticleNavi"> Article Navigation</span></button></td></tr></tbody></table><!--<banner--><nav><div id="mySidenav" class="sidenav" aria-hidden="true" tabindex="-1" role="region" aria-labelledby="sidebar_title"><span id="sidebar_title" class="navHead" align="center">Article Navigation</span><a href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#" aria-label="Close article navigation" class="closebtn" onclick="closeNav(true)" tabindex="-1"><span aria-hidden="true">×</span></a><a href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#" class="navAbs" onclick="closeNav(false)" tabindex="-1">Abstract</a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec1"><span style="vertical-align: top;">1</span><span style="display:inline-block;margin-left:5px;width:80%">
 INTRODUCTION</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec2"><span style="vertical-align: top;">2</span><span style="display:inline-block;margin-left:5px;width:80%">
 LITERATURE REVIEW</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3"><span style="vertical-align: top;">3</span><span style="display:inline-block;margin-left:5px;width:80%">
 METHODOLOGY</span></a><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3Z1"> <span style="vertical-align: top;">3.1</span><span style="display:inline-block;margin-left:5px;width:80%">
 Data Collection</span></a><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3Z2"> <span style="vertical-align: top;">3.2</span><span style="display:inline-block;margin-left:5px;width:80%">
 Study Procedures</span></a><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3Z3"> <span style="vertical-align: top;">3.3</span><span style="display:inline-block;margin-left:5px;width:80%">
 Measures</span></a><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3Z4"> <span style="vertical-align: top;">3.4</span><span style="display:inline-block;margin-left:5px;width:80%">
 Statistical Analysis</span></a><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec3Z5"> <span style="vertical-align: top;">3.5</span><span style="display:inline-block;margin-left:5px;width:80%">
 Analysis</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec4"><span style="vertical-align: top;">4</span><span style="display:inline-block;margin-left:5px;width:80%">
 RESULTS</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec5"><span style="vertical-align: top;">5</span><span style="display:inline-block;margin-left:5px;width:80%">
 DISCUSSION</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#sec6"><span style="vertical-align: top;">6</span><span style="display:inline-block;margin-left:5px;width:80%">
 CONCLUSION</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#ack-001"><span style="vertical-align: top;"></span><span style="display:inline-block;margin-left:5px;width:80%">ACKNOWLEDGMENTS</span></a><hr><a class="navLista" onclick="closeNav(false)" style="display:list-item;" tabindex="-1" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib-sec-001"><span style="vertical-align: top;"></span><span style="display:inline-block;margin-left:5px;width:80%">REFERENCES</span></a></div></nav></banner>
<main>
<section class="front-matter">
<section>
<header class="title-info">
<div class="journal-title">
<h1>
<span class="title">Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease: Asthma</span>
<br>
<span class="subTitle">Analysis of Side Effects after using Moderna, Pfizer and Janssen Vaccine Based on VAERS Dataset</span>
</h1>
</div>
</header>
<div class="authorGroup">
<div class="author">
<a href="https://orcid.org/0000-0002-2824-3093" ref="author"><span class="givenName">MD Imtiaz</span> <span class="surName">Hasan</span></a>, 
Computer Science and Engineering, American International University-Bangladesh, Bangladesh, <a href="mailto:imtiaz.hasan121@gmail.com">imtiaz.hasan121@gmail.com</a>
</div>
<div class="author">
<a href="https://orcid.org/0000-0001-9176-2665" ref="author"><span class="givenName">Mehjabin</span> <span class="surName">Hossain</span></a>, 
Computer Science and Engineering, American International University-Bangladesh,, Bangladesh, <a href="mailto:mehjabinlikhi@gmail.com">mehjabinlikhi@gmail.com</a>
</div>
<div class="author">
<span class="givenName">MD Nazmul</span> 
<span class="surName">Hossain</span>, American Inernational University-Bangladesh, Bangladesh, <a href="mailto:nazmul@aiub.edu">nazmul@aiub.edu</a>
</div>
<div class="author">
<span class="givenName">Kawser</span> 
<span class="givenName">Irom</span> 
<span class="surName">Rushee</span>, American Inernational University-Bangladesh, Bangladesh, <a href="mailto:rushee@aiub.edu">rushee@aiub.edu</a>
</div>
</div>
<br>
<div class="pubInfo">
<p>DOI: <a href="https://doi.org/10.1145/3542954.3543001" target="_blank">https://doi.org/10.1145/3542954.3543001</a>
<br>ICCA 2022: <a href="https://doi.org/10.1145/3542954" target="_blank">2nd International Conference on Computing Advancements</a>, Dhaka, Bangladesh, March 2022</p>
</div>
<div class="abstract">
<p><small>Vaccination could be a critical preventative strategy against coronavirus disease 2019 (COVID-19), and it is essential to understand the vaccine's usability in the general population. A safe and effective vaccination is the most effective way to terminate this epidemic. Many communities throughout the globe have expressed concerns regarding the efficacy and side effects of coronavirus SARS CoV2 vaccinations. Vaccines are now being rushed to market. Many papers have been published on COVID-19 vaccine, hesitancy, acceptance rate, local survey, vaccine distribution, vaccine information, etc. However, none of them mentioned any potential side effects from the COVID-19 vaccination for those with pre-existing disease like Asthma. The study aimed to describe the possible side effects after getting COVID-19 vaccines (Moderna, Pfizer and Janssen) for those who have a pre-existing disease like Asthma.</small></p>
</div>
<div class="CCSconcepts">
<ccs2012><small> <span style="font-weight:bold;">CCS Concepts:</span></small> <span class="keyword"><small>Computing methodologies-&gt;Machine learning-&gt;Machine learning approaches-&gt;Logical and relational learning-&gt;Statistical relational learning;500.</small></span> </ccs2012>
</div>
<br>
<div class="classifications">
<div class="author">
<span style="font-weight:bold;"><small>KEYWORDS:</small></span>
<span class="keyword"><small>COVID-19 side effect</small>, </span>
<span class="keyword"><small>Asthma effect</small>, </span>
<span class="keyword"><small>Types of symptoms</small>, </span>
<span class="keyword"><small>VAERS dataset</small>, </span>
<span class="keyword"><small>Age</small>, </span>
<span class="keyword"><small>SARS-CoV-2</small></span>
</div>
<br>
<div class="AcmReferenceFormat">
<p><small>
<span style="font-weight:bold;">ACM Reference Format:</span>
<br>Md Imtiaz, and Hasan, Mehjabin, and Hossain, Md Nazmul, and Hossain and Kawser Irom, and Rushee. 2022. Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease: Asthma: Analysis of Side Effects after using Moderna, Pfizer and Janssen Vaccine Based on VAERS Dataset. In <em>2nd International Conference on Computing Advancements (ICCA 2022), March 10-12, 2022, Dhaka, Bangladesh</em>. ACM, New York, NY, USA, 10 Pages. <a class="link-inline force-break" href="https://doi.org/10.1145/3542954.3543001">https://doi.org/10.1145/3542954.3543001</a></small></p>
</div>
</div>
</section>
</section>
<section class="body">
<section id="sec1">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">1</span></span> INTRODUCTION</h2>
</div>
</header>
<p>COVID-19 is a coronavirus that has not been identified before 2019 which is found in Wuhan, China [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib9" data-original-title="" title="" id="auto-bib91">9</a>]. Vaccines are one of the best inventions saving millions of lives against Covid-19. There are some vaccines, such as Moderna, Pfizer, and Janssen. Among these vaccines, Moderna is the most effective and most used vaccine. However, all these vaccines have side effects. Our main aim is to identify the side effects after using the vaccines. The shortage of adequate and accepted COVID-19 cure creates a vaccine evolution race from November 11, 2020 [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib11" data-original-title="" title="" id="auto-bib112">11</a>].</p>
<p>However, these vaccinations have rised the risk of vaccine protection issues. The vaccine development process begins immediately the viral genomic sequence is disclosed in January [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib10" data-original-title="" title="" id="auto-bib103">10</a>]. The most crucial distinction is the wide variety of technological platforms used to build a COVID-19 vaccine. In reverse, some of these platforms have never been extensively utilized before. The Pfizer-BioNTech vaccine has been approved as the first product. Coronavirus vaccines have never been licensed for use in humans. One commonly raised topic is if the vaccine's safety and efficacy are jeopardized by its rapid development. The broad acceptance of COVID-19 immunization programs is critical to their effectiveness. However, although immunizations give substantial safety and security, they do not confer complete impunity and while they may limit viral broadcasting to others, this amount of this reduction is unknown. This creates a problem for communicators who want to be clear about the advantages and risks and promote continuous vigilance among vaccinated people while not undermining public trust in a critical public health strategy [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib13" data-original-title="" title="" id="auto-bib134">13</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib14" data-original-title="" title="" id="auto-bib145">14</a>].</p>
<p>Vaccination is a medical practice that is intrusive and has well-defined dangers to the person [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib15" data-original-title="" title="" id="auto-bib156">15</a>]. As such, it is viewed as an individual medical choice in some countries and needs informed agreement (Others consider it as a general fitness policy that may forced in need of the choice of agreement or turndown [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib16" data-original-title="" title="" id="auto-bib167">16</a>-<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib19" data-original-title="" title="" id="auto-bib198">19</a>]). Until recently, because there was minimal evidence that the COVID-19 immunizations reduced disease transmission to others, they were better referred to as separate rather than a general safety method. Countless people would declare that sharing what is now known about COVID-19 vaccinations transparently and openly should be deemed vital from an ethical position [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib19" data-original-title="" title="" id="auto-bib199">19</a>], independent of any predicted influence of such statements on people's vaccination intentions [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib20" data-original-title="" title="" id="auto-bib2010">20</a>].</p>
<p>Several cross-sectional studies conducted across the globe have shown that people's willingness to become vaccinated against COVID-19 is strongly influenced by their views of the vaccine's safety and effectiveness [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib26" data-original-title="" title="" id="auto-bib2611">26</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib27" data-original-title="" title="" id="auto-bib2712">27</a>–<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib32" data-original-title="" title="" id="auto-bib3213">32</a>]. People who aren't willing to get the COVID-19 vaccine because they don't think it's safe or effective are "universally" the same people, according to a recent review of similar research [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib25" data-original-title="" title="" id="auto-bib2514">25</a>]. Vaccination rejection or delay is often attributed to worry about protection and benefit, according to surveys of COVID-19 vaccine hesitating participants [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib29" data-original-title="" title="" id="auto-bib2915">29</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib33" data-original-title="" title="" id="auto-bib3316">33</a>–<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib37" data-original-title="" title="" id="auto-bib3717">37</a>]. Qualitative investigations have also raised worries concerning the COVID-19 vaccine's safety and effectiveness [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib31" data-original-title="" title="" id="auto-bib3118">31</a>–<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib33" data-original-title="" title="" id="auto-bib3319">33</a>]. COVID-19 vaccination fears may be fueled by misinformation, which has been found to correlate with COVID-19 vaccine hesitation in a recent study [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib36" data-original-title="" title="" id="auto-bib3620">36</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib37" data-original-title="" title="" id="auto-bib3721">37</a>].</p>
</section>
<section id="sec2">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">2</span></span> LITERATURE REVIEW</h2>
</div>
</header>
<p>During December 2019, SARS-CoV-2, a coronavirus, came out [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib1" data-original-title="" title="" id="auto-bib122">1</a>], causes COVID-19. Vaccinations are one of the principal ways to dispose of COVID-19 [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib2" data-original-title="" title="" id="auto-bib223">2</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib11" data-original-title="" title="" id="auto-bib1124">11</a>], saving millions of lives each year. These immunizations, however, have specific adverse effects. In observational case series from China, Europe, and South America, the incidence of asthma illness among COVID-19 individuals has been relatively low. Patients hospitalized with COVID-19, on the other hand, had a greater frequency of asthma. As a result, it's still uncertain if asthma is a risk factor for severe COVID-19. SARS-CoV-2 might potentially be a cause for asthma exacerbations, according to theory [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib1" data-original-title="" title="" id="auto-bib125">1</a>]. Also, most cells may be antiviral, and eosinopenia, rather than eosinophilia, may indicate serious COVID-19.</p>
<p>Further comprehensive multi-center studies are required to understand the complicated link in the middle of SARS-CoV-2 contamination along with asthma fully. And effect of SARS-CoV-2 on exhausted infection is unknown beyond the serious stage of the aggressive infection. Because SARS-CoV-2 is a inhaling sickness, pleura damage is likely. According to research, in comparison to healthy people, victims along with COVID-19 which were released by the hospital exhibited deficient pulmonary gas-exchange performance. After three months of follow-up, there is no difference in the time it takes for asthmatics and no asthmatics to resolve lower respiratory symptoms [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib3" data-original-title="" title="" id="auto-bib326">3</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib8" data-original-title="" title="" id="auto-bib827">8</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib12" data-original-title="" title="" id="auto-bib1228">12</a>]. Nonetheless, single retrospective research is inadequate to resolve all present ambiguities and misunderstandings about the subject.</p>
<p>There are least long-term data on the result of SARS-CoV-2 contamination to asthma, also these effects of the COVID-19 vaccine with this illness is unknown [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib4" data-original-title="" title="" id="auto-bib429">4</a>]. The influence of COVID immunization on asthma should be considered, particularly in this accumulate to pile vaccination of teenager and kids [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib5" data-original-title="" title="" id="auto-bib530">5</a>]. According to American research, the expedited schedule for vaccine development, mistrust in scientific and medical communities, and entrenched institutional racist practices were cited as factors for reluctance and opposition to COVID-19 vaccinations. Vaccine side effects, defined as phenotypic responses of the human body to pharmacological therapy or simply lousy drug reactions, are the most definite cause of this apprehension. Side effects are a sign of vaccine antigenicity and immunogenicity, hence the vaccine's ability to elicit immunological responses.</p>
<p>Vaccine adverse effects are classified as either short-term or long-term depending on when they appear after immunization. Injection site adverse effects such as discomfort, redness, and swelling at the injection site and accompanying lymph nodes and systemic side effects such as headache, malaise, joint pain, fever or chills, nausea, and vomiting have been documented with presently licensed COVID-19 vaccinations. COVID-19 vaccinations, on the other hand, have just recently been approved and utilized. Therefore, long-term adverse effects are unclear. Some immunological ideas and case studies, on the other hand, may give some insight into these long-term adverse effects. Confident investigators speculated that the SARS-CoV-2 spike glycoprotein might resemble some human peptide-protein sequences, implying the possibility of cross-reaction. [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib6" data-original-title="" title="" id="auto-bib631">6</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib9" data-original-title="" title="" id="auto-bib932">9</a>] Nonetheless, the danger is the same as it is with other immunizations.</p>
<p>Serum antibody levels and anti-receptor binding domains to the virus that causes COVID-19, were looked at in hundred healthy volunteers who had been vaccinated with the Moderna, Janssen or Pfizer-BioNTech vaccines 2–6 weeks after they had been fully vaccinated. According to the present research, both vaccinations effectively protect against SARS-CoV-2 infection. The Pfizer/BioNTech Vaccine is indicated for persons aged 16 and over. It is 95 percent effective in preventing SARS-COV-2 disease and provides immunogenicity for at least 119 days following the initial immunization. On the other hand, Moderna Vaccine has been recommended for persons aged 18 and over. Also, most cells may be antiviral, and eosinopenia, rather than eosinophilia, may be an indication of severe COVID-19. Both vaccinations, however, have been linked to adverse reactions in some people. Injection site discomfort, redness, swelling, exhaustion, headache, muscle pain, nausea, vomiting, itching, chills, and joint pain are all possible side reaction of the COVID-19 vaccine, moreover anaphylactic shock in rare cases. When differentiate to the Moderna vaccine, Pfizer/BioNTech vaccine has been shown to have fewer side effects [<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib7" data-original-title="" title="" id="auto-bib733">7</a>,<a class="bib" data-trigger="hover" data-toggle="popover" data-placement="top" href="https://camps.aptaracorp.com/ACM_PMS/PMS/ACM/ICCA2022/47/d4c76709-e56f-11ec-a76e-16bb50361d1f/OUT/icca2022-47.html#bib10" data-original-title="" title="" id="auto-bib1034">10</a>].</p>
</section>
<section id="sec3">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3</span></span> METHODOLOGY</h2>
</div>
</header>
<section id="sec3Z1">
<header>
<div class="title-info">
<h3>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3.1</span></span> Data Collection</h3>
</div>
</header>
<p>This data was collected from Vaccine Adverse Event Reporting System (VAERS) website, between January 2021 to November 2021, which contains Pfizer, Moderna and Janssen vaccines. After preparation the dataset, we made same graph about Lineplot, Countplot and pie charts.</p>
</section>
<section id="sec3Z2">
<header>
<div class="title-info">
<h3>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3.2</span></span> Study Procedures</h3>
</div>
</header>
<p>(VAERS) is a nationwide early warning system that detects potential safety issues in the United States. VAERS receives and reviews reports of adverse events after a person has received a vaccination (possible side effects). In the dataset, a total of 890837 individual's data were collected. Among them, Asthma 8239, Hypertension 3061, High Blood Pressure 2378, Hypothyroidism 2335, etc. The highest pre-existing disease was Asthma, about 8239. We calculated different types of symptoms in females and males affected by Asthma. We made some graph about Lineplot Female vs Male based on ‘Age’ (10-100), Countplot based on ‘Different Types of Symptoms’ and specific on Female, Lineplot based on Asthma, using Moderna on Female, Age(10-100), Pie Chart based on Asthma, using <img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image1.png" class="img-responsive" alt=""> on Female, Age(20-40) and Pie Chart based on Asthma, using <img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image1.png" class="img-responsive" alt=""> on Male, Age(20-40).</p>
</section>
<section id="sec3Z3">
<header>
<div class="title-info">
<h3>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3.3</span></span> Measures</h3>
</div>
</header>
<p>SARS-CoV-2, which causes COVID-19, has spread rapidly around the globe, producing varying degrees of sickness. Vaccines are one of the most successful COVID-19 eradication techniques. SARS-Cov2 coronaviruses cause COVID-19, and new vaccinations have been discovered to protect people against the illness. In this paper, every graph was made using Google Colab and Python language. Following the preparation of the dataset, all charts were created. These graphs were made after testing the accuracy of the dataset using the Decision Tree Algorithm and Random Forest Tree Algorithm. For the accuracy test, 80% of data was for training and 20% of data was for testing. After testing, the accuracy-test was about 0.7132 and the value accuracy was about 0.3711.</p>
</section>
<section id="sec3Z4">
<header>
<div class="title-info">
<h3>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3.4</span></span> Statistical Analysis</h3>
</div>
</header>
<p>Asthma was the most common pre-existing condition, accounting for 8239 people. We estimated several forms of symptoms in female and male patients with Asthma. In this dataset, different types of symptoms were found. One type of symptoms was found in more than 1000 people, two types of symptoms were found in less than 1500 people, three types of symptoms were found in nearly 1500 people, four types of symptoms were found in more than 1000 people and five types of symptoms were found more than 3000 people.</p>
</section>
<section id="sec3Z5">
<header>
<div class="title-info">
<h3>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">3.5</span></span> Analysis</h3>
</div>
</header>
<p>In this prospective experimental study, we examine the dataset and side effects with vaccination in individuals using the COVID -19 vaccination result who accepted at the minimum 1 portion of COVID-19 preventive, Moderna, Pfizer, and Janssen. We found the highest pre-existing disease was Asthma in the dataset. And we also found different types of symptoms in those who are affected by Asthma. In the previous research, we can see much paper about COVID -19, vaccine hesitancy, vaccine acceptance, Safety and Efficacy, but none of them are about Asthma or different types of symptoms related.</p>
</section>
</section>
<section id="sec4">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">4</span></span> RESULTS</h2>
</div>
</header>
<figure id="fig1">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image2.png" class="img-responsive" alt="Figure 1">
<figcaption>
<span class="figure-number">Figure 1:</span>
<span class="figure-title">Lineplot Female vs Male based on ‘Age’</span>
</figcaption>
</figure>
<p>The Line graph compares females vs. males based on ages 10 to 100 with different types of symptoms after getting the COVID-19 vaccine. Overall, this graph says females are more affected than males after getting the COVID-19 vaccine. The upper chart mentioned female's different types of symptoms, and the lower graph mentioned Males' different kinds of symptoms. We can see middle-aged females were more affected with different types of symptoms than middle-aged Males. In addition, we can see the probability of 3 types and 4 type's symptoms were mostly affected. In addition, we can see Females who were 80 to 90 aged, where a higher rate of the victim than Males.</p>
<figure id="fig2">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image3.png" class="img-responsive" alt="Figure 2">
<figcaption>
<span class="figure-number">Figure 2:</span>
<span class="figure-title">Countplot based on ‘Different Types of Symptoms’</span>
</figcaption>
</figure>
<p>This countplot graph shows the Different types of symptoms based on Females and Males who were 10 to 100 aged after getting the COVID-19 vaccine. In this countplot graph, one kind of symptom affected people was more than 1000. Also, 2 and 3 types of symptoms were slightly different and nearly 1500. And four types of symptoms were slightly higher than 1000. Overall, we can see five types of symptoms mostly affected females and males. It was more than 3000.</p>
<figure id="fig3">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image4.png" class="img-responsive" alt="Figure 3">
<figcaption>
<span class="figure-number">Figure 3:</span>
<span class="figure-title">Countplot based on ‘Different Types of Symptoms’ on Female</span>
</figcaption>
</figure>
<p>This countplot graph shows the Different types of symptoms based on Females who were 10 to 100 aged after getting the COVID-19 vaccine (Moderna, Pfizer, and Janssen). Overall, we can see five types of symptoms mainly affected females other than Males. It was more than 2500. In this countplot graph, one symptom that affected females was nearly 1000. Also, 2 and 3 types of symptoms were slightly different and almost 1000. And the last four types of symptoms were nearly 900.</p>
<figure id="fig4">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image5.png" class="img-responsive" alt="Figure 4">
<figcaption>
<span class="figure-number">Figure 4:</span>
<span class="figure-title">Lineplot based on Asthma, using Moderna on Female; Age (10-100)</span>
</figcaption>
</figure>
<p>This Line graph shows the different types of symptoms based on females who were 10-100 aged and had a pre-existing disease like Asthma after getting the Moderna vaccine. In this line graph, Females were more affected by different types of symptoms than Males. And we can see the probability of 3 types and 4 type's symptoms mainly were concerned. Females aged 20 to 50 were mostly affected by 3 or 4 types of symptoms.</p>
<figure id="fig5">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image6.png" class="img-responsive" alt="Figure 5">
<figcaption>
<span class="figure-number">Figure 5:</span>
<span class="figure-title">Pie Chart based on Asthma, using PFIZER \ BIONTECH on Male; Age (20-40)</span>
</figcaption>
</figure>
<p>This pie chart graph shows the Different types of symptoms based on males who were 20 to 40 aged after getting the COVID-19 vaccine Pfizer/Biontech. And they had a pre-existing disease like Asthma. There were different percentages for different types of symptoms. In this chart, the highest types of signs were about 38.5%, and the lowest type was approximately 13.4%. 2 types of symptoms affected males about 16.0%. Three types of symptoms affected males about 18.4%. 4 types of symptoms about 13.4% involved males.</p>
<figure id="fig6">
<img src="./Possible Side Effects after Getting COVID-19 Vaccine Based on Pre-Existing Disease_ Asthma_files/image7.png" class="img-responsive" alt="Figure 6">
<figcaption>
<span class="figure-number">Figure 6:</span>
<span class="figure-title">Pie Chart based on Asthma, using PFIZER \ BIONTECH on Female; Age (20-40)</span>
</figcaption>
</figure>
<p>This pie chart shows the Different types of symptoms based on females who were 20 to 40 aged after getting the COVID-19 Pfizer/Biontech vaccine. And they had a pre-existing disease like Asthma. There were different percentages for different types of symptoms. Overall, five types of symptoms mainly were affected on females compared to other symptoms. There was one type of symptom that affected females about 14.9%. Then, two types of symptoms involved on female about 15.8%. After that, three types of symptoms, about 15.7%, and four types of symptoms, about 13.6%, affected females. Lastly, the number of 5 symptoms was more involved on the female than 40.1%.</p>
</section>
<section id="sec5">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">5</span></span> DISCUSSION</h2>
</div>
</header>
<p>The impact of age, marital status, gender, education, allergy, health condition, past COVID-19 infection, and vaccination type on the risk of subjects experiencing side effects after receiving the vaccine were investigated using logistic regression. Female gender, rising age, and receiving the initial dosage were all linked to a higher risk of adverse effects after vaccination.</p>
<p>Our study showed several side effects were recorded after getting COVID-19 immunization, including soreness at the injection site, hypertension, high blood pressure, hypothyroidism resulting from pre-existing conditions such as Asthma, and especially after the first dose of vaccination. Female participants and those who got the Moderna vaccine had considerably more reported adverse effects. Among three (Moderna, Pfizer, Janssen) vaccines, Moderna was the highest acceptance rate.</p>
</section>
<section id="sec6">
<header>
<div class="title-info">
<h2>
<span class="section-number"><span class="nav-open" role="button" onclick="openNav(this)" title="article navigation" tabindex="0">6</span></span> CONCLUSION</h2>
</div>
</header>
<p>Local side effects, such as discomfort and redness at the injection site, were the most common for the three vaccines produced by Moderna, Pfizer, and Janssen. Moderna vaccination caused the most musculoskeletal discomfort, fever, chills, exhaustion, headache, nausea and vomiting, and anxiety, followed by Pfizer vaccine and finally Janssen vaccine. It was shown that females were more likely than males to have symptoms after the COVID-19 vaccine. The observed symptoms were generally well tolerated; nevertheless, further study and examinations into long-term effects and safety profiles are needed.</p>
<p>Finally, both immunizations have a low frequency, low intensity, and short-term side effect profile. Younger persons, women, and those who have previously had COVID-19 are more likely to have side effects. The effects of immunization normally last a few days following the injection. Our data might be utilized to warn patients about the risk of negative side effects depending on their age, sex, and vaccination type. Furthermore, our results support those of randomized controlled trials done in a large community-based context, which indicated evidence of possible post-immunization side effects.</p>
</section>
</section>
<section class="back-matter">
<section id="ack-001">
<header>
<div class="title-info">
<h2><span class="nav-open" role="button" onclick="openNav(this)" tabindex="0" title="article navigation">ACKNOWLEDGMENTS</span></h2>
</div>
</header>
<p>The authors express their appreciation to the dean, director, and department head of American International University-Bangladesh (AIUB) for their support throughout the publication process, which took place during a coronavirus outbreak. Also, a special thanks to the supervisor.</p>
</section>
<section id="bib-sec-001">
<header>
<div class="title-info">
<h2 class="page-brake-head"><span class="nav-open" role="button" onclick="openNav(this)" tabindex="0" title="article navigation">REFERENCES</span></h2>
</div>
</header>
<ul class="bibUl">
<li id="bib1" label="[1]" value="1">Sarah Schaffer DeRoo, Natalie J. Pudalov and Linda Y. Fu. 2020. "Planning for a COVID-19 vaccination program." Jama 323, no. 24 (2020): 2458-2459. DOI: <a class="link-inline force-break" href="https://doi.org/10.1001/jama.2020.8711">https://doi.org/10.1001/jama.2020.8711</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 1" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib122" aria-label="citation 1 reference 1">citation 1</option><option value="#auto-bib125" aria-label="citation 2 reference 1">citation 2</option></select></li>
<li id="bib2" label="[2]" value="2">Balsam Qubais Saeed, Rula Al-Shahrabi, Shaikha Salah Alhaj, Zainab Mansour Alkokhardi, and Ahmed Omar Adrees.2021. "Side effects and perceptions following Sinopharm COVID-19 vaccination." International Journal of Infectious Diseases 111 (2021): 219-226. DOI: <a class="link-inline force-break" href="https://doi.org/10.1101/2021.06.28.21258847">https://doi.org/10.1101/2021.06.28.21258847</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 2" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib223" aria-label="citation 1 reference 2">citation 1</option></select></li>
<li id="bib3" label="[3]" value="3">Giulia Carli, Lorenzo Cecchi, Justin Stebbing, Paola Parronchi and Alessandro Farsi. 2020. "Is asthma protective against COVID‐19?." Allergy (2020). DOI: <a class="link-inline force-break" href="https://doi.org/10.1111/all.14426">https://doi.org/10.1111/all.14426</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 3" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib326" aria-label="citation 1 reference 3">citation 1</option></select></li>
<li id="bib4" label="[4]" value="4">SARS-CoV-2 Immunity Persists for Up To 11 Months After Natural Infection. (2021, June 8). News-Medical.net. Retrieved February 15, 2022, from <a class="link-inline force-break" href="https://www.news-medical.net/news/20210608/SARS-CoV-2-immunity-persists-for-up-to-11-months-after-natural-infection.aspx">https://www.news-medical.net/news/20210608/SARS-CoV-2-immunity-persists-for-up-to-11-months-after-natural-infection.aspx</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 4" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib429" aria-label="citation 1 reference 4">citation 1</option></select></li>
<li id="bib5" label="[5]" value="5">Kawthar Mohamed, Piotr Rzymski, Md Shahidul Islam, Rangarirai Makuku, Ayesha Mushtaq, Amjad Khan, Mariya Ivanovska <em>et al.</em> "COVID‐19 vaccinations: The unknowns, challenges, and hopes." Journal of medical virology (2021). Retrieved February 15, 2022, from <a class="link-inline force-break" href="https://onlinelibrary.wiley.com/doi/10.1002/jmv.27487">https://onlinelibrary.wiley.com/doi/10.1002/jmv.27487</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 5" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib530" aria-label="citation 1 reference 5">citation 1</option></select></li>
<li id="bib6" label="[6]" value="6">PRIME PubMed. 2021. COVID-19 Vaccines: Comparison Of Biological, Pharmacological Characteristics And Adverse Effects Of Pfizer/BioNTech And Moderna Vaccines. (n.d.). PRIME PubMed | COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines (2021). Retrieved February 15, 2022,from <a class="link-inline force-break" href="https://neuro.unboundmedicine.com/medline/citation/33629336/COVID_19_vaccines:_comparison_of_biological_pharmacological_characteristics_and_adverse_effects_of_Pfizer/BioNTech_and_Moderna_Vaccines_">https://neuro.unboundmedicine.com/medline/citation/33629336/COVID_19_vaccines:_comparison_of_biological_pharmacological_characteristics_and_adverse_effects_of_Pfizer/BioNTech_and_Moderna_Vaccines_</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 6" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib631" aria-label="citation 1 reference 6">citation 1</option></select></li>
<li id="bib7" label="[7]" value="7">Alexzandra Hughes-Visentin, and Anthea B Mahesan Paul.2020. "Asthma and COVID-19: what do we know now." Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine 14 (2020). DOI: <a class="link-inline force-break" href="https://doi.org/10.1177/1179548420966242">https://doi.org/10.1177/1179548420966242</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 7" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib733" aria-label="citation 1 reference 7">citation 1</option></select></li>
<li id="bib8" label="[8]" value="8">Jonathan Sprent, and Cecile King.2021. "COVID-19 vaccine side effects: The positives about feeling bad." Science immunology 6, no. 60 (2021): eabj9256. DOI: <a class="link-inline force-break" href="https://doi.org/10.1126/sciimmunol.abj9256">https://doi.org/10.1126/sciimmunol.abj9256</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 8" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib827" aria-label="citation 1 reference 8">citation 1</option></select></li>
<li id="bib9" label="[9]" value="9">Lu Lu, Weixi Xiong, Jie Mu, Qi Zhang, Hesheng Zhang, Ling Zou, Weimin Li, Li He, Josemir W.Sander, and Dong Zhou. 2021. "The potential neurological effect of the COVID‐19 vaccines: a review." Acta Neurologica Scandinavica (2021). DOI: <a class="link-inline force-break" href="https://doi.org/10.1111/ane.13417">https://doi.org/10.1111/ane.13417</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 9" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib91" aria-label="citation 1 reference 9">citation 1</option><option value="#auto-bib932" aria-label="citation 2 reference 9">citation 2</option></select></li>
<li id="bib10" label="[10]" value="10">Cristina Menni, Kerstin Klaser, Anna May, Lorenzo Polidori, Joan Capdevila, Panayiotis Louca, Carole Sudre. 2021. "Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study." The Lancet Infectious Diseases 21, no. 7 (2021): 939-949. DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/S1473-3099(21)00224-3">https://doi.org/10.1016/S1473-3099(21)00224-3</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 10" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib103" aria-label="citation 1 reference 10">citation 1</option><option value="#auto-bib1034" aria-label="citation 2 reference 10">citation 2</option></select></li>
<li id="bib11" label="[11]" value="11">Haya Omeish, Angam Najadat, Sayer Azzam, Nada Tarabin, Amer Abu Hameed, Neebal Al-Gallab, Hadeel Abbas. 2021. "Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study." Human Vaccines &amp; Immunotherapeutics (2021): 1-8. DOI: <a class="link-inline force-break" href="https://doi.org/10.1080/21645515.2021.1981086">https://doi.org/10.1080/21645515.2021.1981086</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 11" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib112" aria-label="citation 1 reference 11">citation 1</option><option value="#auto-bib1124" aria-label="citation 2 reference 11">citation 2</option></select></li>
<li id="bib12" label="[12]" value="12">Bover-Bauza C , Rosselló Gomila MA, Díaz Pérez D , Millán Pons AR, Gil Sánchez JA, Peña-Zarza JA, Figuerola Mulet J, Osona B. 2021. "The impact of the SARS-CoV-2 pandemic on the emergency department and management of the pediatric asthmatic patient." Journal of Asthma and Allergy 14 (2021): 101. DOI: <a class="link-inline force-break" href="https://doi.org/10.2147/JAA.S284813">https://doi.org/10.2147/JAA.S284813</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 12" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib1228" aria-label="citation 1 reference 12">citation 1</option></select></li>
<li id="bib13" label="[13]" value="13">WHO. 2021. (2021, March 9). Weekly epidemiological update - 9 March 2021. Retrieved February 15, 2022, from <a class="link-inline force-break" href="https://www.who.int/publications/m/item/weekly-epidemiological-update%E2%80%9410-march-2021">https://www.who.int/publications/m/item/weekly-epidemiological-update—10-march-2021</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 13" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib134" aria-label="citation 1 reference 13">citation 1</option></select></li>
<li id="bib14" label="[14]" value="14">GMC. 2021. Covid 19 Questions and Answers - GMC. Retrieved February 15, 2022, from <a class="link-inline force-break" href="https://www.gmc-uk.org/ethical-guidance/ethical-hub/covid-19-questions-and-answers">https://www.gmc-uk.org/ethical-guidance/ethical-hub/covid-19-questions-and-answers</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 14" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib145" aria-label="citation 1 reference 14">citation 1</option></select></li>
<li id="bib15" label="[15]" value="15">Rebecca Forman, Soleil Shah, Patrick Jeurissen, Mark Jit and Elias Mossialos. 2020. "COVID-19 vaccine challenges: What have we learned so far and what remains to be done?." Health Policy 125, no. 5 (2021): 553-567. DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.healthpol.2021.03.013">https://doi.org/10.1016/j.healthpol.2021.03.013</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 15" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib156" aria-label="citation 1 reference 15">citation 1</option></select></li>
<li id="bib16" label="[16]" value="16">Giulia Russo, Valentina Di Salvatore, Filippo Caraci, Cristina Curreli, Marco Viceconti and Francesco Pappalardo. 2021. "How can we accelerate COVID-19 vaccine discovery?." Expert opinion on drug discovery 16, no. 10 (2021): 1081-1084. DOI: <a class="link-inline force-break" href="https://doi.org/10.1080/17460441.2021.1935861">https://doi.org/10.1080/17460441.2021.1935861</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 16" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib167" aria-label="citation 1 reference 16">citation 1</option></select></li>
<li id="bib17" label="[17]" value="17">Marwan ElBagoury, Mahmoud M.Tolba, Hebatallah A. Nasser, Abdul Jabbar, Ahmed M. Elagouz, Yahia Aktham and Amy Hutchinson. 2021. "The find of COVID-19 vaccine: Challenges and opportunities." Journal of infection and public health 14, no. 3 (2021): 389-416. DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.jiph.2020.12.025">https://doi.org/10.1016/j.jiph.2020.12.025</a></li>
<li id="bib18" label="[18]" value="18">Jennifer Neill. 2020. "Case for persuasion in parental informed consent to promote rational vaccine choices." Journal of medical ethics (2020). DOI: <a class="link-inline force-break" href="https://doi.org/10.1136/medethics-2020-106068">https://doi.org/10.1136/medethics-2020-106068</a></li>
<li id="bib19" label="[19]" value="19">Johns Hopkins Medicine. 2021. What Is Coronavirus? (January 1, 2021). Retrieved February 15, 2022, from <a class="link-inline force-break" href="https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus">https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus</a>. <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 19" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib198" aria-label="citation 1 reference 19">citation 1</option><option value="#auto-bib199" aria-label="citation 2 reference 19">citation 2</option></select></li>
<li id="bib20" label="[20]" value="20">Julio Emilio Marco-Franco, Pedro Pita-Barros, David Vivas-Orts, Silvia Gonzalez-de-Julián and David Vivas-Consuelo. 2020."COVID-19, fake news, and vaccines: should regulation be implemented?" International Journal of Environmental Research and Public Health 18, no. 2 (2021): 744. DOI: <a class="link-inline force-break" href="https://doi.org/10.3390/ijerph18020744">https://doi.org/10.3390/ijerph18020744</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 20" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib2010" aria-label="citation 1 reference 20">citation 1</option></select></li>
<li id="bib21" label="[21]" value="21">Cheryl Lin, Pikuei Tu, Leslie M. Beitsch. 2020. Confidence And Receptivity for COVID-19 Vaccines: A Rapid Systematic Review. (2020, December 30). MDPI. DOI: <a class="link-inline force-break" href="https://doi.org/10.3390/vaccines9010016">https://doi.org/10.3390/vaccines9010016</a></li>
<li id="bib22" label="[22]" value="22">Md Abul Kalam, Thomas P.Davis Jr., Shahanaj Shano, Nasir Uddin, Md.Ariful Islam, Robert Kanwagi, Ariful Islam, Mohammad Mahmudul Hassan and Heidi J. Larson. 2021. "Exploring the behavioral determinants of COVID-19 vaccine acceptance among an urban population in Bangladesh: Implications for behavior change interventions." (2021) DOI: <a class="link-inline force-break" href="https://doi.org/10.1101/2021.04.23.21255974">https://doi.org/10.1101/2021.04.23.21255974</a></li>
<li id="bib23" label="[23]" value="23">Yulan Lin, Qinjian Zhao, Haridah Alias, Mahmoud Danaee, Li Ping Wong. (2020, December 17). Understanding COVID-19 Vaccine Demand And Hesitancy: A Nationwide Online Survey In China. Understanding COVID-19 vaccine demand and hesitancy: A nationwide online survey in China. DOI: <a class="link-inline force-break" href="https://doi.org/10.1371/journal.pntd.0008961">https://doi.org/10.1371/journal.pntd.0008961</a></li>
<li id="bib24" label="[24]" value="24">Linda C. Karlsson, Anna Soveri, Stephan Lewandowsky, Linnea Karlsson, Hasse Karlsson, Saara Nolvi, Max Karukivi, Mikael Lindfelt, and Jan Antfolk. 2021. "Fearing the disease or the vaccine: The case of COVID-19." Personality and individual differences 172 (2021): 110590. DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.paid.2020.110590">https://doi.org/10.1016/j.paid.2020.110590</a></li>
<li id="bib25" label="[25]" value="25">PubMed Central (PMC). Interim Estimates Of Vaccine Effectiveness Of Pfizer-BioNTech And Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021. (2021, May 21). Retrieved from <a class="link-inline force-break" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136422/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8136422/</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 25" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib2514" aria-label="citation 1 reference 25">citation 1</option></select></li>
<li id="bib26" label="[26]" value="26">Timothy Callaghan, Ali Moghtaderi, Jennifer A.Lueck, Peter Hotez, Ulrich Strych, Avi Dor, Erika Franklin Fowler, and Matthew Motta. 2021. "Correlates and disparities of intention to vaccinate against COVID-19." Social Science &amp; Medicine (2021). DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.socscimed.2020.113638">https://doi.org/10.1016/j.socscimed.2020.113638</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 26" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib2611" aria-label="citation 1 reference 26">citation 1</option></select></li>
<li id="bib27" label="[27]" value="27">Elise Paul, Andrew Steptoe, and Daisy Fancourt. "Attitudes towards vaccines and intention to vaccinate against COVID-19: Implications for public health communications." The Lancet Regional Health-Europe 1 (2021). DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.lanepe.2020.100012">https://doi.org/10.1016/j.lanepe.2020.100012</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 27" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib2712" aria-label="citation 1 reference 27">citation 1</option></select></li>
<li id="bib28" label="[28]" value="28">Li Ping Wong, Haridah Alias, Pooi-Fong Wong, Hai Yen Lee, and Sazaly AbuBakar. 2020. "The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay." Human vaccines &amp; immunotherapeutics 16, no. 9 (2020): 2204-2214. DOI: <a class="link-inline force-break" href="https://doi.org/10.1080/21645515.2020.1790279">https://doi.org/10.1080/21645515.2020.1790279</a></li>
<li id="bib29" label="[29]" value="29">Kimberly A. Fisher, Sarah J.Bloomstone, Jeremy Walder, Sybil Crawford, Hassan Fouayzi, and Kathleen Mazor. 2020. "Attitudes toward a potential SARS-CoV-2 vaccine: a survey of US adults." Annals of internal medicine 173, no. 12 (2020): 964-973. DOI: <a class="link-inline force-break" href="https://doi.org/10.7326/M20-3569">https://doi.org/10.7326/M20-3569</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 29" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib2915" aria-label="citation 1 reference 29">citation 1</option></select></li>
<li id="bib30" label="[30]" value="30">Kristyn Frank and Rubab Arim. 2020. "Canadians' Willingness to Get a COVID-19 Vaccine when One Becomes Available: What Role Does Trust Play?" (2020).</li>
<li id="bib31" label="[31]" value="31">Takeshi Yoda, and Hironobu Katsuyama. "Willingness to receive COVID-19 vaccination in Japan." Vaccines 9, no. 1 (2021). DOI: <a class="link-inline force-break" href="https://doi.org/10.3390/vaccines9010048">https://doi.org/10.3390/vaccines9010048</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 31" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib3118" aria-label="citation 1 reference 31">citation 1</option></select></li>
<li id="bib32" label="[32]" value="32">Jeanette B.Ruiz, and Robert A.Bell. 2021. "Predictors of intention to vaccinate against COVID-19: Results of a nationwide survey." Vaccine 39, no. 7 (2021): 1080-1086. DOI: <a class="link-inline force-break" href="https://doi.org/10.1016/j.vaccine.2021.01.010">https://doi.org/10.1016/j.vaccine.2021.01.010</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 32" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib3213" aria-label="citation 1 reference 32">citation 1</option></select></li>
<li id="bib33" label="[33]" value="33">Amiel A. Dror, Netanel Eisenbach, Shahar Taiber, Nicole G. Morozov, Matti Mizrachi, Asaf Zigron, Samer Srouji, and Eyal Sela. 2020. "Vaccine hesitancy: the next challenge in the fight against COVID-19." European journal of epidemiology 35, no. 8 (2020): 775-779. DOI: <a class="link-inline force-break" href="https://doi.org/10.1007/s10654-020-00671-y">https://doi.org/10.1007/s10654-020-00671-y</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 33" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib3316" aria-label="citation 1 reference 33">citation 1</option><option value="#auto-bib3319" aria-label="citation 2 reference 33">citation 2</option></select></li>
<li id="bib34" label="[34]" value="34">Florence   Momplaisir, Norrisa Haynes, Hervette Nkwihoreze, Maria Nelson, Rachel M. Werner, and John Jemmott. "Understanding drivers of coronavirus disease 2019 vaccine hesitancy among blacks." Clinical Infectious Diseases 73, no. 10 (2021): 1784-1789. DOI: <a class="link-inline force-break" href="https://doi.org/10.1093/cid/ciab102">https://doi.org/10.1093/cid/ciab102</a></li>
<li id="bib35" label="[35]" value="35">Trinidad Beleche, Joel Ruhter, Allison Kolbe, Jessica Marus, Laina Bush and Benjamin Sommers. 2021. "COVID-19 Vaccine Hesitancy: Demographic Factors, Geographic Patterns, and Changes over Time." Published online 27 (2021).</li>
<li id="bib36" label="[36]" value="36">Bridget Lockyer, Shahid Islam, Aamnah Rahman, Josie Dickerson, Kate Pickett, Trevor Sheldon, John Wright, Rosemary McEachan and Laura Sheard. "Understanding COVID‐19 misinformation and vaccine hesitancy in context: Findings from a qualitative study involving citizens in Bradford, UK." Health Expectations 24, no. 4 (2021): 1158-1167. DOI: <a class="link-inline force-break" href="https://doi.org/10.1111/hex.13240">https://doi.org/10.1111/hex.13240</a> <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 36" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib3620" aria-label="citation 1 reference 36">citation 1</option></select></li>
<li id="bib37" label="[37]" value="37">Lynn Williams, Allyson J. Gallant, Susan Rasmussen, Louise A. Brown Nicholls, Nicola Cogan, Karen Deakin, David Young, and Paul Flowers. 2020. "Towards intervention development to increase the uptake of COVID‐19 vaccination among those at high risk: Outlining evidence‐based and theoretically informed future intervention content." British Journal of Health Psychology 25, no. 4 (2020): 1039-1054. DOI: https: //doi.org/10.1111/bjhp.12468 <span class="link-das"> </span><select class="bib-ref-num" aria-label="Jump to citation for reference 37" style="display:inline-block;"><option>Navigate to</option><option value="#auto-bib3717" aria-label="citation 1 reference 37">citation 1</option><option value="#auto-bib3721" aria-label="citation 2 reference 37">citation 2</option></select></li>
</ul>
</section>
</section>
<section id="foot-001" class="footnote">
<div class="bibStrip">
<p>Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from <a href="mailto:permissions@acm.org">permissions@acm.org</a>.</p>
<p><em>ICCA 2022, March 10–12, 2022, Dhaka, Bangladesh</em></p>
<p>© 2022 Association for Computing Machinery.<br> ACM ISBN 978-1-4503-9734-6/22/03…$15.00.<br>DOI: <a class="link-inline force-break" target="_blank" href="https://doi.org/10.1145/3542954.3543001">https://doi.org/10.1145/3542954.3543001</a>
</p>
</div>
</section>
</main>

<quillbot-extension-portal></quillbot-extension-portal></body><quillbot-extension-root></quillbot-extension-root></html>